In a report released today, Serge Belanger from Needham maintained a Buy rating on GW Pharma (GWPH), with a price target of $180.00. The company’s shares closed last Tuesday at $107.11.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -1.2% and a 34.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for GW Pharma with a $173.75 average price target, representing a 79.1% upside. In a report released today, Northland Securities also reiterated a Buy rating on the stock with a $150.00 price target.
See today’s analyst top recommended stocks >>
Based on GW Pharma’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $121 million and GAAP net loss of $8.83 million. In comparison, last year the company earned revenue of $72.04 million and had a net profit of $79.75 million.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GWPH in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.